Sommaire

• Editorial

  • ·Accelerating Innovations for Enhanced Brain Health. Can Artificial Intelligence Advance New Pathways for Drug Discovery for Alzheimer’s and other Neurodegenerative Disorders?

    Page :1-4

    A.S. Khachaturian, A. Dengel, V. Dočkal, P. Hroboň, M. Tolar

    Plan Plan
  • ·Change on Clinical Trial Outcome Assessments: The Search for Meaningfulness

    Page :5-6

    Jeffrey Cummings

    
  • ·Usefulness of Anchor Based Methods for Determining Clinically Meaningful Change in MCI due to AD

    Page :7-8

    Suzanne B. Hendrix, S.P. Dickson, Pentara Corporation

     

• Original Research

  • ·Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer’s Disease

    Page :9-18

    Claire J. Lansdall, F. McDougall, L.M. Butler, P. Delmar, N. Pross, S. Qin, L. McLeod, X. Zhou, G.A. Kerchner, R.S. Doody

    Résumé Résumé Plan Plan   
  • ·ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

    Page :19-24

    Eric Siemers, J. Hitchcock, K. Sundell, R. Dean, J. Jerecic, E. Cline, K. Iverson, J. Moore, C. Edgar, R. Manber, N. Fuin, T. Poppe, R. Barton

    Résumé Résumé Plan Plan  
  • ·Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer’s and Parkinson’s Patients

    Page :25-33

    Cheng Fang, P. Hernandez, K. Liow, E. Damiano, H. Zetterberg, K. Blennow, D. Feng, M. Chen, M. Maccecchini

    Résumé Résumé Plan Plan   
  • ·US Adults’ Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging

    Page :34-40

    Chelsea G. Cox, M.A. Davis, J.D. Grill, J.S. Roberts

    Résumé Résumé Plan Plan  
  • ·The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer’s Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    Page :41-49

    Edmond Teng, P.T. Manser, M. Shah, K. Pickthorn, N. Hu, S. Djakovic, H. Swendsen, M. Blendstrup, G. Faccin, S. Ostrowitzki, K.M. Sink

    Résumé Résumé Plan Plan   

• Review

  • ·Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010–2020

    Page :50-68

    N. Navarro-Gómez, M. Valdes-Gonzalez, B.B. Garrido-Suárez, Gabino Garrido

    Résumé Résumé Plan Plan  

• Systematic Review

  • ·Gender-Specific Design and Effectiveness of Non-Pharmacological Interventions against Cognitive Decline — Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Page :69-82

    Andrea E. Zülke, S.G. Riedel-Heller, F. Wittmann, A. Pabst, S. Röhr, M. Luppa

    Résumé Résumé Plan Plan   

• Review

  • ·Socioeconomic Status and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 39 Prospective Studies

    Page :83-94

    A.-Y. Wang, H.-Y. Hu, Y.-N. Ou, Z.-T. Wang, Y.-H. Ma, Lan Tan, Jin-Tai Yu

    Résumé Résumé Plan Plan   
  • ·Programmed Death of Microglia in Alzheimer’s Disease: Autophagy, Ferroptosis, and Pyroptosis

    Page :95-103

    Z. Qiu, H. Zhang, M. Xia, J. Gu, K. Guo, H. Wang, Changhong Miao

    Résumé Résumé Plan Plan  

• Original Research

  • ·Age- and Sex-Different Associations between Cognitive Performance and Inflammatory Biomarkers in Community Dwelling Older Adults: towards Precision Preventive Strategies

    Page :104-111

    B.-A. Chen, W.-J. Lee, C.-P. Chung, L.-N. Peng, Liang-Kung Chen

    Résumé Résumé Plan Plan  
  • ·Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer’s Disease

    Page :112-119

    Kellen K. Petersen, A. Ezzati, R.B. Lipton, B.A. Gordon, J. Hassenstab, J.C. Morris, E. Grober

    Résumé Résumé Plan Plan   
  • ·Systematic and Comparative Analysis of the Burden of Alzheimer’s Disease and Other Dementias in Mexico. Results at the National and Subnational Levels, 1990–2019

    Page :120-129

    M. Agudelo-Botero, L. Giraldo-Rodríguez, Mario E. Rojas-Russell

    Résumé Résumé Plan Plan  

• Short Communication

  • ·Demographic Analysis of Industry-Sponsored Alzheimer’s Disease Trial Populations in the United States

    Page :130-132

    Stephen J. Peroutka

    Résumé Résumé Plan Plan  

• Brief Reports

  • ·Risk Estimates of Dementia and Alzheimer’s Disease among Different Whole Grain Food Consumption Categories: A Pilot Study

    Page :133-136

    Kanran Wang, Qin Zhou

    Résumé Résumé Plan Plan
  • ·Prevention of Alzheimer’s Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference

    Page :137-143

    M.S. Hershey, M. Sotos-Prieto, S. Andrieu, A. Hofman, P. Magiatis, M.A. Martinez-Gonzalez, M. Yannakoulia, Stefanos N. Kales, N. Scarmeas

    Résumé Résumé Plan Plan
  • ·Embryo Selection for a Carrier of an Early-Onset Alzheimer’s Disease-Associated Mutation in the PSEN1 Gene

    Page :144-147

    O.H. Valdés-Martínez, S.M. García-Luna, L.C. Oceguera-Palao, L. Villarreal-Pineda, L.H. Sordia-Hernández, B. de la Fuente Cortez, Felipe Arturo Morales-Martínez

    Résumé Résumé Plan Plan

• Letter to the Editor

  • ·AMBAR: A Therapeutical Approach for Alzheimer’s Disease Patients Regardless of Amyloid Status

    Page :148-149

    Montserrat Costa, M. Boada

    

• Erratum

  • ·Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats

    Page :150

    B. Souchet, M. Audrain, Y. Gu, M.F. Lindberg, N.S. Orefice, E. Rey, N. Cartier, N. Janel, L. Meijer, Jérôme Braudeau

    Résumé Résumé
  • ·Erratum to: Alzheimer’s Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer’s Disease

    Page :151

    Suzanne B. Hendrix, H. Soininen, A.M.J. van Hees, N. Ellison, P.J. Visser, A. Solomon, A. Attali, K. Blennow, M. Kivipelto, T. Hartmann